-
Methylergonovine
- indication:For the prevention and control of excessive bleeding following vaginal childbirth
- pharmacologypharmacology:
- mechanism: Methylergonovine acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions through binding and the resultant antagonism of the dopamine D1 receptor. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss.
- toxicity: Signs and symptoms of overexposure: hypertension, seizures, headache, hypotension, nausea, and vomiting.
- absorprion: Absorption is rapid after oral (60% bioavailability) and intramuscular (78% bioavailability) administration.
- halflife: 3.39 hours
- roouteelimination: Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver.
- volumedistribution: * 56.1 ± 0 L
- clearance: